Dose first patient in Phase 1/2 study of BEAM-301
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 13 Jan 2025
- Due
- 31 Mar 2025
- Delivered
- by 6 May 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Dose first patient in Phase 1/2 study in early 2025”
What we found
Evidence strength A What the grades mean
The company announced in May 2025 that it had dosed the first patient in the BEAM-301 Phase 1/2 study, which occurred after the 'early 2025' deadline.
-
A Beam Therapeutics Inc. 10-Q filed 2025-05-06
“In May 2025, we announced the dosing of the first patient in the trial.” ✓ confirmed on the page
Market reaction: the shares moved -13.2% against the S&P 500 over the three sessions around the disclosure (5 May 2025 to 8 May 2025). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Dose
- Deliverable
- BEAM-301 GSD1a Phase 1/2 study
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-BEAM-003295 · Corrections policy